Pastor Olaya

Pastor Olaya

Auto-generated profile, based on publicly available information

Pastor Olaya

Servicio de Cardiología, Fundación Valle del Lili, Cali, Valle del Cauca, Colombia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2021 in Case Reports in Cardiology
Verified
Journal Article
Open access
PDF file
JRJulián Alejandro Rivillas
Julián Alejandro Rivillas
SGStephania Galindo-Coral
Stephania Galindo-Coral
FAFrancisco Arias-Mora
Francisco Arias-Mora
JLJuan David Lopez
Juan David Lopez
NFNoel Alberto Florez-Alarcón
Noel Alberto Florez-Alarcón
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Background. Neurological complications occur between 50 and 70% of patients with heart transplantation, including cerebrovascular events, infections, seizures, encephalopathy, and neurotoxicity due to pharmacological immunosuppression. Mortality associated with cerebrovascular complications is 7.5% in the first 30 days and up to 5.3% after the first month and up to the first year after transplantation. Case Reports. Three heart-transplanted patients (2 men and 1 woman) treated with tacrolimus were identified. They presented with posterior reversible encephalopathy syndrome on days 5, 6, and 58 posttransplantation, respectively. In these reported cases, no sequelae were observed at 6 months follow-up. Conclusions. Posterior reversible encephalopathy syndrome as a neurological complication in patients with HT occurred early after the procedure. Early diagnosis and treatment might reduce the risk of serious complications and mortality.

1 February 2020 in CASE
Verified
Journal Article
Open access
GGGerman Camilo Giraldo-Gonzalez
German Camilo Giraldo-Gonzalez
POPastor Olaya
Pastor Olaya
ADAndrés Domínguez
Andrés Domínguez
JSJairo Sanchez
Jairo Sanchez
CVCarlos Enrique Vesga
Carlos Enrique Vesga
• Thrombosis of devices as amplatzer could happen late as in this case, 8 years after. • Caution should be exercised with symptoms suggestive of embolism • A formal anticoagulation regimen may be sufficient in some cases. • Individualized follow up and treatment is required with this type of devices.

17 October 2023 in Transplant Infectious Disease
Verified
Journal Article
Closed access
DCDiana Cristina Carrillo‐Gómez
Diana Cristina Carrillo‐Gómez
CRCristhian Camilo Rojas‐Perdomo
Cristhian Camilo Rojas‐Perdomo
NENicolas Orozco Echeverri
Nicolas Orozco Echeverri
MMMaria C. Montes
Maria C. Montes
LFLiliana Flórez‐Elvira
Liliana Flórez‐Elvira
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa

4 July 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
PCPaula Andrea Cárdenas-Marín
Paula Andrea Cárdenas-Marín
JZJorge Alexander Zambrano-Franco
Jorge Alexander Zambrano-Franco
MRMaria Juliana Reyes-Cardona
Maria Juliana Reyes-Cardona
CCCamilo Andres Calderon-Miranda
Camilo Andres Calderon-Miranda
JSJairo Sanchez-Blanco
Jairo Sanchez-Blanco
CVCarlos Enrique Vesga-Reyes
Carlos Enrique Vesga-Reyes
Background: Persistent left superior vena cava (PLSVC) is the most common thoracic venous anomaly and is often associated with complex congenital heart disease (CHD). Venous drainage typically occurs into the right atrium via the coronary sinus (CS). However, in 10–20% of cases, it drains into the left atrium, producing a right-to-left shunt that may result in symptoms and cerebrovascular complications. Case presentation: A 23-year-old woman with a history of double-outlet right ventricle corrected at age 13 presented in the postpartum period with dysarthria, left central facial palsy and left hemiparesis. Brain MRI angiography revealed right middle cerebral artery (M2) occlusion, and she underwent thrombolysis and thrombectomy. Suspecting a cardioembolic event, transesophageal echocardiography with left-arm agitated saline injection revealed early left atrial opacification and delayed right-sided filling via a residual ventricular septal defect —suggesting a PLSVC draining into the left atrium. Cardiac CT confirmed CS agenesis and a PLSVC connected to the left atrial roof. She was discharged on enoxaparin. Conclusions: PLSVC is a vascular anomaly with an estimated prevalence of 0.2-3% in the general population and 1-12% among CHD patients. A dilated CS on transthoracic echocardiography should prompt a bubble test; early opacification of the left chambers after left-arm saline injection suggests drainage to the left atrium. Cardiac CT, MRI or invasive angiography can clarify the anatomy. PLSVC has clinical implications including technical considerations for percutaneous procedures and cardiac surgery, a predisposition for arrhythmias, and —when draining into the left atrium— an increased risk of cerebrovascular events. Closure of a PLSVC draining into the left atrium should be considered in symptomatic patients or those at high risk of paradoxical embolism, following anatomical assessment. In pregnant women with CHD, cardiac risk assessment, multimodal imaging and multidisciplinary follow-up are crucial due to associated hemodynamic changes and hypercoagulable state.

14 January 2026 in Global Heart
Verified
Journal Article
Open access
JLJuan David Lopez
Juan David Lopez
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
Alejandro Toro-PedrozaAlejandro Toro-Pedroza
Alejandro Toro-Pedroza
JAJuan Pablo Arango-Ibanez
Juan Pablo Arango-Ibanez
VAValeria Azcarate-Rodriguez
Valeria Azcarate-Rodriguez
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Background: Heart transplantation (HT) remains the definitive treatment for advanced heart failure that is refractory to both medical and invasive therapies. Although global registries offer extensive data on survival outcomes, there is a relative paucity of information regarding HT outcomes in Latin America (LATAM), particularly in Colombia. Methods: This study analyzed adult patients who underwent HT between 1995 and 2024, using data obtained from an institutional HT registry (RETRAC) in Cali, Colombia. Survival outcomes were evaluated using Kaplan–Meier curves and Cox proportional hazards models. Results: We included 260 patients who underwent HT in this 29-year cohort from a LATAM country. The median age at transplantation was 51 years, and 77.7% were male. The primary etiologies were idiopathic/dilated cardiomyopathy (IDC) (41.3%), ischemic cardiomyopathy (IC) (27.0%), and valvular heart disease (VHC) (9.7%). The most prevalent comorbidities were hypertension (HTN) (48.3%), diabetes mellitus (DM) (18.9%), and chronic kidney disease (CKD) (13.1%). The overall median survival following HT was 7.4 years. One-year survival was 74.6% (n = 194), five-year survival was 56.9% (n = 147), and ten-year survival was 46.9% (n = 122). Survival differed significantly by age and sex, with patients aged <40 years demonstrating the highest median survival (8.4 years) and those aged ≥60 years the lowest (2.2 years) (p = 0.038). The 40- to 49-year age group exhibited the most pronounced reduction in survival; however, this effect was attenuated after adjustment. Among patients under 40 years, females had significantly higher mortality compared to males (p = 0.0078), with younger males exhibiting better survival. Additionally, patients transplanted between 2016 and 2020 had higher survival rates. CKD was identified as a significant independent risk factor for increased mortality (hazard ratio (HR) = 1.79; 95% CI: 1.15–2.79; p = 0.01). Conclusions: HT patients in Colombia exhibit demographic and clinical profiles comparable to global cohorts; however, they demonstrate lower survival rates and poorer clinical outcomes compared to international registries, such as the International Society for Heart and Lung Transplantation registry. Nonetheless, clinical outcomes are more favorable than those reported in other studies from the LATAM region. CKD emerged as a significant independent predictor of mortality. These findings highlight the need for region-specific strategies aimed at improving HT outcomes in LATAM.

16 October 2025 in American Journal of Case Reports
Verified
Journal Article
Open access
CCCamilo Andres Calderon-Miranda
Camilo Andres Calderon-Miranda
LZLuz Clemencia Zárate-Correa
Luz Clemencia Zárate-Correa
MRMaría Juliana Reyes-Cardona
María Juliana Reyes-Cardona
POPastor Olaya
Pastor Olaya
JSJairo Sanchez-Blanco
Jairo Sanchez-Blanco
CVCarlos Enrique Vesga-Reyes
Carlos Enrique Vesga-Reyes
BACKGROUND Mycotic aortic aneurysms (MAA) are rare but life-threatening infections of the arterial wall, characterized by rapid progression, a high risk of rupture, and poor outcomes. They most frequently occur in immunocompromised or chronically ill patients, including those with diabetes, renal failure, or on long-term hemodialysis. Early diagnosis and prompt multidisciplinary management are critical for improving survival. CASE REPORT We present the case of a 58-year-old woman with end-stage renal disease on hemodialysis via arteriovenous fistula, who was admitted with fever, gastrointestinal symptoms, and respiratory distress. Blood and pleural fluid cultures isolated methicillin-resistant Staphylococcus aureus (MRSA). Transesophageal echocardiography (TEE) and computed tomography angiography (CTA) identified a saccular aneurysm of the descending thoracic aorta, consistent with a mycotic aneurysm. Given the severity of the infection and the patient's hemodynamic instability, a hybrid approach was chosen, involving endovascular aneurysm repair (EVAR) followed by open thoracotomy for pleural debridement and empyema drainage. Despite targeted antibiotic therapy and surgical intervention, the patient developed massive intraoperative hemorrhage and refractory septic shock, ultimately resulting in death 4 days postoperatively. Intraoperative cultures of the aortic wall confirmed MRSA infection. CONCLUSIONS MAA is a diagnostic and therapeutic challenge with high morbidity and mortality, particularly in high-risk populations. Imaging modalities such as CTA and TEE are essential for early diagnosis. Management typically involves prolonged intravenous antibiotics and either surgical, endovascular, or hybrid repair. Despite aggressive treatment, the prognosis is poor, underscoring the need for further research to guide optimal treatment strategies and improve outcomes.